Phase 3 Parkinson's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC), confirmed by a lab test on a tissue or cell sample.
• Your doctor has determined that certain targeted treatments (aimed at specific gene changes called EGFR, ALK, or ROS1) are not the right first treatment for you.
• A lab test on your tumor tissue shows that at least 50% of your cancer cells have a protein called PD-L1 on their surface.
• You are fairly active and able to care for yourself, with only mild limitations on daily activities (confirm with trial site for exact fitness level required), assessed within 7 days before joining the trial.
• Your doctor expects you to live for at least 3 months.
• If you have HIV, it must be well controlled with HIV medication.

Who may not be able to join:

• You have a type of lung cancer called small cell lung cancer, or your tumor contains small cell elements.
• You have moderate or severe nerve damage causing weakness, numbness, or pain (Grade 2 or higher peripheral neuropathy).
• You have a history of serious dry eye syndrome, serious eyelid gland disease, or serious corneal problems that affect healing.
• You have active inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) that requires immune-suppressing medication, or you have a clear history of these conditions.
• You have had serious heart or blood vessel problems in the 6 months before starting the trial.
• You have already received any systemic (whole-body) cancer treatment for your advanced (metastatic) NSCLC.
• You have previously been treated with certain immune checkpoint drugs (anti-PD-1, anti-PD-L1, or anti-PD-L2), unless that treatment was given before surgery for early-stage lung cancer and finished at least 12 months before your cancer spread.
• You have received any systemic cancer treatment, including experimental drugs, within the 4 weeks before joining the trial.
• You have received high-dose radiation to the lungs (more than 30 Gy) within the 6 months before starting the trial.
• You have received any radiotherapy within 2 weeks before starting the trial, or you still have side effects from radiation that require steroid treatment.
• You have received a live vaccine within 30 days before your first dose of the trial treatment.
• You have been diagnosed with an immune system deficiency, or you are regularly taking steroid medication.
• You have another cancer that is growing or has needed active treatment within the past 3 years.
• You have active cancer that has spread to the brain or the lining around the brain and spinal cord.
• You have a known allergy or intolerance to either of the trial drugs (sacituzumab tirumotecan or pembrolizumab) or their ingredients, including a serious allergic reaction to pembrolizumab.
• You have a known serious allergy to sacituzumab tirumotecan or similar biological medicines.
• You have an autoimmune disease (where the immune system attacks the body) that has needed treatment in the past 2 years.
• You have a history of serious lung inflammation (pneumonitis or interstitial lung disease) that required steroid treatment, or you currently have this condition.
• You have an active infection that requires treatment with medication taken throughout the body.
• You have both hepatitis B and hepatitis C infections at the same time.
• You have HIV and also have a history of a cancer called Kaposi's sarcoma or a condition called Multicentric Castleman's Disease.
• You have previously received a transplant of an organ or tissue from another person.
• You need to take certain medications that strongly affect how your body processes the trial drug (strong CYP3A4 inhibitors or inducers) during the trial period (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.